ClinicalTrials.gov
public full text
Public Domain
Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome
In the era of hypomethylating agent in MDS treatment, the investigators aimed to investigate the prognostic impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2) on the outcomes of 1st line decitabine treatment in MDS.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The development of spliceosome inhibition with RNA probing and sequencing for the characterization of intronic secondary structures from cellular environments#685196
- Preliminary Reliability and Validity of SynapTrack, a Smartphone-Based Digital Biomarker Platform for Remote Assessment of Cervical Spondylotic Myelopathy#377113
- Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response#359883
- Tandem splice acceptor sites: Profiling their relevance to human disease.#334808
- Analysis of spliceosome-related coding and noncoding genes and pseudogenes reveals novel candidates#660940
Record · ID 858101
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive